Dashboard E. coli
Repurposing candidates for E. coli
Escherichia coli
Approved medicines with AI-predicted activity ≥40% against E. coli, leaving out medicines that are already antimicrobials. Each is shown with what it is already used for. They are surfaced computationally for further investigation, not as treatments.
- AI-predicted activity ≥40%
- 467
- Existing antimicrobials set aside
- 103
- Needing review
- 28
- Repurposing candidates
- 336
Repurposing candidates for E. coli
AI prediction · nothing measuredAll 336 repurposing candidates for E. coli.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Tenofovir Alafenamide FumarateExisting use: Chronic hepatitis B virus infection, Hepatitis B virus infection, HIV infection and 2 more42.3% AI-predicted activityagainst E. coli50+ registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more42.3% AI-predicted activityagainst E. coli50+ registered studies
- Griseofulvin, MicrosizeExisting use: Candidiasis, Infection, Tinea and 1 more42.3% AI-predicted activityagainst E. coli9 registered studies
- Remimazolam BesylateExisting use: Sedation42.3% AI-predicted activityagainst E. coli50+ registered studies
- Serdexmethylphenidate ChlorideExisting use: Attention deficit hyperactivity disorder42.2% AI-predicted activityagainst E. coli2 registered studies
- Nelfinavir MesylateExisting use: HIV infection, HIV-1 infection42.2% AI-predicted activityagainst E. coli50+ registered studies
- LinagliptinExisting use: Diabetes mellitus, Type 2 diabetes mellitus42.1% AI-predicted activityagainst E. coli50+ registered studies
- MoxidectinExisting use: Helminthiasis, Onchocerciasis42.1% AI-predicted activityagainst E. coli25 registered studies
- Azelastine HydrochlorideExisting use: Allergic conjunctivitis, Allergic disease, Allergic rhinitis and 5 more42.0% AI-predicted activityagainst E. coli48 registered studies
- Mycophenolate MofetilExisting use: Delayed Graft Function, Immune system disease, Multiple sclerosis42.0% AI-predicted activityagainst E. coli50+ registered studies
- Fostemsavir TromethamineExisting use: HIV infection, HIV-1 infection, Immunodeficiency disease and 1 more42.0% AI-predicted activityagainst E. coliNo documented evidence found
- AmisulprideExisting use: Nausea and vomiting, Post operative nausea and vomiting, Psychosis42.0% AI-predicted activityagainst E. coli50+ registered studies
- BaricitinibExisting use: Rheumatoid arthritis42.0% AI-predicted activityagainst E. coli50+ registered studies
- PonesimodExisting use: Multiple sclerosis, Relapsing-remitting multiple sclerosis41.8% AI-predicted activityagainst E. coli22 registered studies
- TeniposideExisting use: Neoplasm41.8% AI-predicted activityagainst E. coli30 registered studies
- TriamtereneExisting use: Cardiovascular disease, Cirrhosis of liver, Congestive heart failure and 5 more41.8% AI-predicted activityagainst E. coli8 registered studies
- Umbralisib TosylateExisting use: Follicular lymphoma, Marginal zone B-cell lymphoma, Neoplasm41.8% AI-predicted activityagainst E. coliNo documented evidence found
- UpadacitinibExisting use: Janus-associated kinase (JAK) inhibitors41.8% AI-predicted activityagainst E. coli50+ registered studies
- Fluticasone PropionateExisting use: Airway obstruction, Allergic rhinitis, Asthma and 9 more41.8% AI-predicted activityagainst E. coli50+ registered studies
- PraziquantelExisting use: Helminthiasis, Infection, Opisthorchiasis and 1 more41.8% AI-predicted activityagainst E. coli50+ registered studies
- SilodosinExisting use: Benign prostatic hyperplasia41.6% AI-predicted activityagainst E. coli50+ registered studies
- Vardenafil HydrochlorideExisting use: Erectile dysfunction, Impotence41.5% AI-predicted activityagainst E. coli7 registered studies
- Atracurium BesylateExisting use: Neuromuscular Blockade41.5% AI-predicted activityagainst E. coli50+ registered studies
- Cisatracurium BesylateExisting use: Other quaternary ammonium compounds41.5% AI-predicted activityagainst E. coli50+ registered studies